Compositions of 7-oxabicycloheptane and 7-oxabicycloheptene compounds and a method for their use in inhibiting bronchoconstriction

A composition for inhibiting bronchoconstriction comprising an effective amount of a compound having the structural formula ##STR59## and including all stereoisomers thereof;

• wherein A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2, B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ;
• m is 1 to 8;
• X is OH;
• ##STR60## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl;
• or ##STR61## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR62## or OR.sup.2 wherein R.sup.2 is H;
• Y is aryl-lower alkyl;
• alkenyl, alkynyl cycloalkyl;
• substituted cycloalkyl;
• cycloalkylalkyl, substituted cycloalkylalkyl, or phenoxymethyl;
• wherein alkyl or lower alkyl by itself or as part of another group contains 1 to 12 carbons, cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion, aryl by itself or as part of another group refers to a monocyclic or bicyclic armomatic ring which contains 6 to 10 carbons in the ring potion, and the cycloalkyl group by itself or as part of another group may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups or lower alkoxy groups (the above substituents not being adjacent to sterically hindered groups);
• and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically accpetable carrier therefor.

A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound having the structural formula ##STR63## and including all stereoisomers thereof;

• wherein A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2, B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ;
• m is 1 to 8;
• X is OH;
• ##STR64## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl;
• or ##STR65## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR66## or OR.sup.2 wherein R.sup.2 is H;
• Y is substituted alkyl (wherein the substituent is halo, lower alkoxy, alkyl-aryl, haloalkyl, cycloalkyl or alkylcycloalkyl) aryl-lower alkyl;
• alkenyl containing 3 to 6 carbons;
• alkynyl containing 3 to 6 carbons;
• aryl (which may be unsubstituted or substituted with lower alkyl, halogen or lower alkoxy), cycloalkyl;
• substituted cycloalkyl;
• cycloalkylalkyl, substituted cycloalkylalkyl, or phenoxymethyl;
• wherein alkyl or lower alkyl by itself or as part of another group contains 1 to 12 carbons, cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion, aryl by itself or as part of another group refers to a monocyclic or bycyclic aromatic ring which contains 6 to 10 carbons in the ring portion, and the cycloalkyl group by itself or as part of another group may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups or lower alkoxy groups (the above substituents not being adjacent to sterically hindered groups);
• and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl, or a pharmaceutically acceptable salt thereof.